AC Immune Ltd Total Assets
AC Immune Ltd total assets. Based on the latest financial reports, AC Immune Ltd (ACIU) holds total assets worth $137.42 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AC Immune Ltd (ACIU) total market value for the company's overall valuation and market capitalisation.
Total Assets of AC Immune Ltd (2013–2025)
Total assets of AC Immune Ltd from 2013 to 2025. This chart illustrates how AC Immune Ltd's total assets have evolved over time, based on quarterly financial data. See latest AC Immune Ltd stock price today for real-time trading data and today's change.
AC Immune Ltd - Asset Composition Analysis
AC Immune Ltd Total Assets Breakdown (December 2025)
AC Immune Ltd total assets breakdown as of December 2025. AC Immune Ltd's total assets of $137.42 Million consist of 62.7% current assets and 37.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.4% |
| Accounts Receivable | $681.77K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $50.47 Million | 32.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how AC Immune Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ACIU net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AC Immune Ltd's current assets represent 62.7% of total assets in 2025, a decrease from 93.8% in 2013.
- Cash Position: Cash and equivalents constituted 17.4% of total assets in 2025, down from 88.2% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 32.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 32.7% of total assets.
AC Immune Ltd Competitors by Total Assets
Key competitors of AC Immune Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
AC Immune Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.87 | 1.53 | 17.12 |
| Quick Ratio | 0.87 | 1.53 | 17.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-12.20 Million | $52.89 Million | $190.96 Million |
AC Immune Ltd - Advanced Valuation Insights
This section examines the relationship between AC Immune Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.71 |
| Latest Market Cap to Assets Ratio | 1.51 |
| Asset Growth Rate (YoY) | -33.1% |
| Total Assets | $154.43 Million |
| Market Capitalization | $233.06 Million USD |
Valuation Analysis
Above Book Valuation: The market values AC Immune Ltd's assets above their book value (1.51x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: AC Immune Ltd's assets decreased by 33.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AC Immune Ltd (2013–2025)
The table below shows the annual total assets of AC Immune Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $154.43 Million | -33.12% |
| 2024-12-31 | $230.91 Million | +26.31% |
| 2023-12-31 | $182.81 Million | -1.68% |
| 2022-12-31 | $185.94 Million | -28.88% |
| 2021-12-31 | $261.44 Million | +9.51% |
| 2020-12-31 | $238.74 Million | -20.22% |
| 2019-12-31 | $299.25 Million | +52.25% |
| 2018-12-31 | $196.56 Million | +48.89% |
| 2017-12-31 | $132.01 Million | -15.43% |
| 2016-12-31 | $156.10 Million | +95.29% |
| 2015-12-31 | $79.93 Million | +163.83% |
| 2014-12-31 | $30.30 Million | +137.60% |
| 2013-12-31 | $12.75 Million | -- |
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more